Suchergebnisse - "Tabernero, J"

PubPharm (30)

1

Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Ros, J. | Matito, J. | Villacampa, G. | +17

2

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370) : a multicentre, open-label, phase 3, randomised, controlled trial

enthalten in: The Lancet. Oncology | 2019

von Eng, C. | Kim, T. | Bendell, J. | +77

CommentIn: Lancet Oncol. 2019 Jun;20(6):752-753. - PMID 31003912

3

Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Yoshino, T. | Portnoy, D. | Obermannová, R. | +19

4

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Tabernero, J. | Hozak, R. | Yoshino, T. | +15

CommentIn: Ann Oncol. 2018 Mar 1;29(3):527-529. - PMID 29360914

5

Professional burnout in European young oncologists : results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Banerjee, S. | Califano, R. | Corral, J. | +16

CommentIn: Ann Oncol. 2017 Sep 1;28(9):2320-2321. - PMID 28520921

6

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Grasselli, J. | Elez, E. | Caratù, G. | +20

7

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2017

von Longo-Muñoz, F. | Argiles, G. | Tabernero, J. | +8

8

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours : the CLARINET open-label extension study

enthalten in: Endocrine-related cancer | 2016

von Caplin, M. | Pavel, M. | Ćwikła, J. | +66

9

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Sclafani, F. | Chau, I. | Cunningham, D. | +16

10

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

enthalten in: British journal of cancer | 2015

von Macarulla, T. | Cervantes, A. | Tabernero, J. | +10